Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Leukemia 41Breast Neoplasms 28Lymphoma 21Leukemia, Myeloid, Acute 16Burkitt Lymphoma 13Myelodysplastic Syndromes 11Graft vs Host Disease 10Lymphoma, Non-Hodgkin 7Lymphoma, Large B-Cell, Diffuse 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Leukemia, Biphenotypic, Acute 7Squamous Cell Carcinoma of Head and Neck 6Urinary Bladder Neoplasms 5Leukemia, Promyelocytic, Acute 5Hodgkin Disease 5Anemia, Refractory, with Excess of Blasts 5Osteosarcoma 4Myeloproliferative Disorders 4Lymphoma, Follicular 4Leukemia, Myelomonocytic, Chronic 4Head and Neck Neoplasms 4Arthritis, Rheumatoid 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Lymphocytic, Chronic, B-Cell 3

Interventions

Cyclophosphamide 3Epirubicin 2Docetaxel 2Carboplatin 2Capecitabine 2Azacitidine 2venetoclax 1tegafur-gimeracil-oteracil 1taxane 1sargramostim 1ruxolitinib 1rucaparib 1pirarubicin 1pertuzumab 1pembrolizumab 1olaparib 1cc-486 1Trastuzumab 1Thalidomide 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Oxaliplatin 1Observation 1Nivolumab 1Monatide (IMS 3015) 1Methotrexate 1Magnetic Resonance Imaging 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Pathologic Complete Response × Methotrexate × Clear all
NCT04314219 2025-03-13

PTCy-PMAT

King Faisal Specialist Hospital & Research Center

Phase 3 Recruiting
264 enrolled
LymphoidOther hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡